The Invion Group is a life sciences group consisting of Invion Limited and its wholly owned subsidiary, Invion Inc., with activities in pharmaceutical drug development. Invion’s expertise and assets target chronic inflammation in two key areas of human health – inflammatory airway disease (or respiratory disease), and inflammation caused by autoimmune disease.
Invion aims to grow a diverse business with a broad pipeline of drug assets that target improved patient outcomes and major commercial opportunities. The Group has three drug assets in development in multiple clinical programs, including three phase II clinical trials currently underway in the United States.
Invion Limited is an ASX listed company (ASX:IVX) with its clinical headquarters in Delaware, USA.